The status of acellular pertussis vaccines: Current perspective

G. Peter, J. G. Easton, N. A. Halsey, M. L. Lepow, E. K. Marcuse, M. I. Marks, G. A. Nankervis, C. F. Phillips, L. K. Pickering, Gwendolyn B Scott, R. W. Steele, K. J. Bart, A. R. Hinman, J. R. La Montagne, N. N E MacDonald, W. A. Orenstein, M. C. Hardegree, R. S. Daum

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

1. The present strategy in the United States of administering three doses of whole-cell pertussis vaccine in early infancy with additional doses at 15 to 18 months and 4 to 6 years of age effectively prevents pertussis. The uniform occurrence of epidemic pertussis in every country that temporarily has abandoned routine pertussis immunization underscores this fact. 2. The Swedish trial and the experience in Japan have provided evidence that acellular vaccines can prevent pertussis with fewer local and systemic reactions than with whole-cell vaccine. 3. Additional efficacy data are needed before one or all of the acellular vaccines can be recommended for routine use in this country during early infancy. 4. The Academy believes that one or more of the acellular pertussis vaccines already used widely in Japan should be considered for introduction in the United States as an alternative to the whole-cell vaccine normally administered at 15 to 18 months of age at the time of school entry.

Original languageEnglish
Pages (from-to)401-405
Number of pages5
JournalPediatrics
Volume88
Issue number2
StatePublished - Dec 1 1991
Externally publishedYes

Fingerprint

Acellular Vaccines
Pertussis Vaccine
Whooping Cough
Japan
Vaccines
Immunization

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Peter, G., Easton, J. G., Halsey, N. A., Lepow, M. L., Marcuse, E. K., Marks, M. I., ... Daum, R. S. (1991). The status of acellular pertussis vaccines: Current perspective. Pediatrics, 88(2), 401-405.

The status of acellular pertussis vaccines : Current perspective. / Peter, G.; Easton, J. G.; Halsey, N. A.; Lepow, M. L.; Marcuse, E. K.; Marks, M. I.; Nankervis, G. A.; Phillips, C. F.; Pickering, L. K.; Scott, Gwendolyn B; Steele, R. W.; Bart, K. J.; Hinman, A. R.; La Montagne, J. R.; MacDonald, N. N E; Orenstein, W. A.; Hardegree, M. C.; Daum, R. S.

In: Pediatrics, Vol. 88, No. 2, 01.12.1991, p. 401-405.

Research output: Contribution to journalArticle

Peter, G, Easton, JG, Halsey, NA, Lepow, ML, Marcuse, EK, Marks, MI, Nankervis, GA, Phillips, CF, Pickering, LK, Scott, GB, Steele, RW, Bart, KJ, Hinman, AR, La Montagne, JR, MacDonald, NNE, Orenstein, WA, Hardegree, MC & Daum, RS 1991, 'The status of acellular pertussis vaccines: Current perspective', Pediatrics, vol. 88, no. 2, pp. 401-405.
Peter G, Easton JG, Halsey NA, Lepow ML, Marcuse EK, Marks MI et al. The status of acellular pertussis vaccines: Current perspective. Pediatrics. 1991 Dec 1;88(2):401-405.
Peter, G. ; Easton, J. G. ; Halsey, N. A. ; Lepow, M. L. ; Marcuse, E. K. ; Marks, M. I. ; Nankervis, G. A. ; Phillips, C. F. ; Pickering, L. K. ; Scott, Gwendolyn B ; Steele, R. W. ; Bart, K. J. ; Hinman, A. R. ; La Montagne, J. R. ; MacDonald, N. N E ; Orenstein, W. A. ; Hardegree, M. C. ; Daum, R. S. / The status of acellular pertussis vaccines : Current perspective. In: Pediatrics. 1991 ; Vol. 88, No. 2. pp. 401-405.
@article{77e5d4ce5e664e7db201c552c28d51e7,
title = "The status of acellular pertussis vaccines: Current perspective",
abstract = "1. The present strategy in the United States of administering three doses of whole-cell pertussis vaccine in early infancy with additional doses at 15 to 18 months and 4 to 6 years of age effectively prevents pertussis. The uniform occurrence of epidemic pertussis in every country that temporarily has abandoned routine pertussis immunization underscores this fact. 2. The Swedish trial and the experience in Japan have provided evidence that acellular vaccines can prevent pertussis with fewer local and systemic reactions than with whole-cell vaccine. 3. Additional efficacy data are needed before one or all of the acellular vaccines can be recommended for routine use in this country during early infancy. 4. The Academy believes that one or more of the acellular pertussis vaccines already used widely in Japan should be considered for introduction in the United States as an alternative to the whole-cell vaccine normally administered at 15 to 18 months of age at the time of school entry.",
author = "G. Peter and Easton, {J. G.} and Halsey, {N. A.} and Lepow, {M. L.} and Marcuse, {E. K.} and Marks, {M. I.} and Nankervis, {G. A.} and Phillips, {C. F.} and Pickering, {L. K.} and Scott, {Gwendolyn B} and Steele, {R. W.} and Bart, {K. J.} and Hinman, {A. R.} and {La Montagne}, {J. R.} and MacDonald, {N. N E} and Orenstein, {W. A.} and Hardegree, {M. C.} and Daum, {R. S.}",
year = "1991",
month = "12",
day = "1",
language = "English",
volume = "88",
pages = "401--405",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "2",

}

TY - JOUR

T1 - The status of acellular pertussis vaccines

T2 - Current perspective

AU - Peter, G.

AU - Easton, J. G.

AU - Halsey, N. A.

AU - Lepow, M. L.

AU - Marcuse, E. K.

AU - Marks, M. I.

AU - Nankervis, G. A.

AU - Phillips, C. F.

AU - Pickering, L. K.

AU - Scott, Gwendolyn B

AU - Steele, R. W.

AU - Bart, K. J.

AU - Hinman, A. R.

AU - La Montagne, J. R.

AU - MacDonald, N. N E

AU - Orenstein, W. A.

AU - Hardegree, M. C.

AU - Daum, R. S.

PY - 1991/12/1

Y1 - 1991/12/1

N2 - 1. The present strategy in the United States of administering three doses of whole-cell pertussis vaccine in early infancy with additional doses at 15 to 18 months and 4 to 6 years of age effectively prevents pertussis. The uniform occurrence of epidemic pertussis in every country that temporarily has abandoned routine pertussis immunization underscores this fact. 2. The Swedish trial and the experience in Japan have provided evidence that acellular vaccines can prevent pertussis with fewer local and systemic reactions than with whole-cell vaccine. 3. Additional efficacy data are needed before one or all of the acellular vaccines can be recommended for routine use in this country during early infancy. 4. The Academy believes that one or more of the acellular pertussis vaccines already used widely in Japan should be considered for introduction in the United States as an alternative to the whole-cell vaccine normally administered at 15 to 18 months of age at the time of school entry.

AB - 1. The present strategy in the United States of administering three doses of whole-cell pertussis vaccine in early infancy with additional doses at 15 to 18 months and 4 to 6 years of age effectively prevents pertussis. The uniform occurrence of epidemic pertussis in every country that temporarily has abandoned routine pertussis immunization underscores this fact. 2. The Swedish trial and the experience in Japan have provided evidence that acellular vaccines can prevent pertussis with fewer local and systemic reactions than with whole-cell vaccine. 3. Additional efficacy data are needed before one or all of the acellular vaccines can be recommended for routine use in this country during early infancy. 4. The Academy believes that one or more of the acellular pertussis vaccines already used widely in Japan should be considered for introduction in the United States as an alternative to the whole-cell vaccine normally administered at 15 to 18 months of age at the time of school entry.

UR - http://www.scopus.com/inward/record.url?scp=0026338550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026338550&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0026338550

VL - 88

SP - 401

EP - 405

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 2

ER -